WHWK
Whitehawk Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.20
+2.94%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$4.09
From 52W high−17.65%
Volume1.94M
Market cap$239.44M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$4.09
From 52W high
−17.65%
Volume
1.94M
Market cap
$239.44M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
P/E (TTM)
—
RSI (14)
43.0
MomentumView details →
1D Return
+2.94%
YTD Return
+72.31%
SummaryUpdated Jun 1, 2026
Whitehawk Therapeutics Inc (NASDAQ:WHWK) is a clinical-stage biopharmaceutical company that underwent a significant strategic transformation in 2024. Originally founded as Aadi Biosciences and going public in 2017, the company initially focused on developing precision therapies for genetically-defined cancers, particularly through its drug FYARRO for rare sarcomas. In late 2024, the company rebranded to Whitehawk Therapeutics and pivoted its strategy to focus on developing advanced antibody-drug conjugates (ADCs) for cancer treatment, while divesting its original FYARRO asset to Kaken Pharmaceuticals.
Similar companies
Latest newsMore news →
Whitehawk Therapeutics presented two real-world analyses at WCLC 2026 in Seoul supporting PTK7 as a durable ADC target in pretreated EGFR wild-type NSCLC, reinforcing the rationale for its next-generation PTK7-directed ADC HWK-007 in Phase 1 development.6d agoWhitehawk Therapeutics appointed Vijay Iyengar as a Class III director effective September 9, 2026, with an initial stock option award for 76,080 shares.10d ago